explore -WSS

explore

author：explore 2025-09-02 08:14:25 - browse：39872

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Chemotherapy shortages won’t get better under Biden’s latest plan

leisure time

WSS

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

UK homeowners get some respite as inflation falls by more than anticipated to a 15

In diabetes hearing, Sanders takes on a new foe: food makers

Pregnancy discrimination could be enabled by AI

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Why you get paid to donate plasma but not blood

hotspot

explore

leisure time

DIEP, the 'gold standard' of breast reconstruction, is under threat

Congenital heart disease patients face new threat of heart failure

After affirmative action ruling, medical educators look to 'holistic review'

Pfizer plans to depart BIO

Alkermes shareholders re

After sickle

Apple is now the first public company to be valued at $3 trillion

Pregnancy discrimination could be enabled by AI

How one medical school became remarkably diverse

SCOTUS to consider access to abortion pill mifepristone

focus

More hospitals are billing patients as online messages surge

House passes resolution saying Israel isn't a 'racist or apartheid state'

Why sickle cell disease is getting the first CRISPR treatment

Chemotherapy shortages won’t get better under Biden’s latest plan

FDA seeking to stop procedures at two unregulated stem cell clinics

What PEPFAR has meant on the ground in Ukraine

knowledge

hotspot

knowledge

leisure time